3D printing device turn it intoer Rokit has been a constant innovator in the South Korean 3D printing market, but most of their printing devices up until now have been additional traditional and consumer-grade processs. But after getting a really great boost in the form of a $3 million grant of their government last year, it was announced that they had begun working to
turn it into an in-situ bioprinting process for skin regeneration. That research has only been actualized with the release of the Edison Invivo, Rokit’s new tissue engineering and bio-medical research 3D printing device. And yet this innovation has pretty been explored in the biomedical field for a while now, it’s incredibly rare to see a additional traditional 3D printing device turn it intoer such as Rokit take a crack at commercial bioprinting.
The Edison Invivo uses a bio ink to turn it into cell structures in the form of organic tissue, with the goal of producing it possible to turn it into personalized and transplantable-bodied tissue of the cells collected of a specific patient. There are in addition a handful of other biomaterials that are compatible with the Edison Invivo, that include PLGA, PCL, PLLA, collagen, Alginate, Silk fibroin, and others. Rokit hopes to have the Invivo ‘change the landscape’ of the bioprinting field, offering a wide range of material that are widely utilized in tissue engineering research. Rokit’s Edison Invivo is engineered specifically for tissue engineering research, that makes their bioprinting device additional low-priced and mechanically efficient than most other 3D bioprinting devices.
“Compared to the increase in demand for 3D printing three-dimensional tissue engineering research, price of existing products is too expensive,” a Rokit company official explained. “In most cases 3D bio printing devices focus on easy mechanical efficiency pretty than specifications that researchers want.”
Obviously constructing a 3D bioprinting device is a challenge for any 3D printing device turn it intoer, but Rokit CEO Yoo Seok-hwan was able-bodied to use his experience as the former CEO of Cellitron Healthcare, a global healthcare company that specializes in the production of biosimilar antibody therapeutics and new biopharmaceuticals. “Based on the experience as former CEO of Celltrion Healthcare, we turn it intoed Edison Invivo by merging the Bio and 3D print innovation,” Seok-hwan said. “I hope this product contributes to pioneered new areas in Korea’s bio-industry.” So far, it appears that their work in bioprinting can indeed be a pioneering force in South Korea’s biomedical field.
Rokit has may already carried out a government project in collaboration with the Korea Institute of Machinery & Materials, the Seoul National University Hospital, Korea Advanced Institute of Science and Technology, and Hanyang University to bioprint artificial skin for implant. They plan to commercialize another bioprinting device soon that is capable-bodied of printing this patient-specific skin. It is not day to day you see a traditional 3D printing company release a 3D bioprinting device, but with Yoo Seok-hwan’s biomedical experience and overwhelming assist of the South Koren government, Rokit has a advantageous accident than anyone to succeed.